PMID- 9797125
OWN - NLM
STAT- MEDLINE
DCOM- 19981110
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 78
IP  - 4
DP  - 1998 Nov 9
TI  - Binding of human anti-DNA autoantibodies to reactive oxygen species modified-DNA 
      and probing oxidative DNA damage in cancer using monoclonal antibody.
PG  - 404-9
AB  - The binding of native and reactive oxygen species-modified DNA (ROS-DNA) to 
      circulating antibodies in the serum of patients with various types of cancer has 
      been investigated by competition enzyme-linked immunosorbent assay. Fifteen sera 
      of 35 showed reactivity with native and/or ROS-DNA. Eleven of these showed higher 
      binding to ROS-DNA (36-64% inhibition), whereas 1 showed higher reactivity with 
      native DNA (nDNA) (42% inhibition). Three sera reacted with both native and 
      ROS-DNA almost equally. Oxidative lesions in human genomic DNA were 
      immunochemically detected using an anti-ROS-DNA monoclonal antibody (MAb) probe. 
      Two of 3 DNA isolates from blood of breast cancer patients, 1 of 3 from lung 
      cancer and 1 of 2 each from hepatocellular cancer and cancer of the gallbladder 
      were reactive with the MAb. Higher recognition of ROS-DNA by circulating 
      antibodies and DNA isolated from cancer patients by the MAb indicates increased 
      oxidative stress leading to DNA damage. Our results suggest that ROS modification 
      of DNA probably alters its immunogenicity leading to the generation of antibodies 
      to ROS-DNA, probably by the activation of autoreactive cells. The induced 
      antibodies against modified DNA are cross-reactive to native DNA.
FAU - Ashok, B T
AU  - Ashok BT
AD  - Department of Biochemistry, Faculty of Medicine, Aligarh Muslim University, 
      India.
FAU - Ali, R
AU  - Ali R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (Reactive Oxygen Species)
SB  - IM
MH  - Adult
MH  - Antibodies, Antinuclear/blood/*immunology
MH  - Antibodies, Monoclonal/immunology
MH  - Antibodies, Neoplasm/blood/*immunology
MH  - Antibody Specificity
MH  - Biomarkers, Tumor/immunology
MH  - *DNA Damage
MH  - DNA, Neoplasm/immunology/*metabolism
MH  - Epitopes/immunology
MH  - Humans
MH  - Middle Aged
MH  - Neoplasms/blood/*genetics/*immunology
MH  - Oxidative Stress
MH  - Prognosis
MH  - Reactive Oxygen Species/*immunology
EDAT- 1998/10/31 03:04
MHDA- 2000/06/20 09:00
CRDT- 1998/10/31 03:04
PHST- 1998/10/31 03:04 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1998/10/31 03:04 [entrez]
AID - 10.1002/(SICI)1097-0215(19981109)78:4<404::AID-IJC2>3.0.CO;2-Y [pii]
AID - 10.1002/(sici)1097-0215(19981109)78:4<404::aid-ijc2>3.0.co;2-y [doi]
PST - ppublish
SO  - Int J Cancer. 1998 Nov 9;78(4):404-9. doi: 
      10.1002/(sici)1097-0215(19981109)78:4<404::aid-ijc2>3.0.co;2-y.